Target
1q21
1 abstract
Abstract
Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+ status: Updated results from the phase 3 IKEMA study.Org: Sanofi, Translational Genomics Research Institute (TGen North), City of Hope Cancer Center, Japanese Red Cross Medical Center,